Background/Aim: Tumoural transcriptional levels of RRM1, RRM2, CDA, dCK and hENT1
genes are potential biomarkers for gemcitabine's efficacy in non-small cell lung cancer …

A number of pharmacogenetic studies have been carried out in non-small-cell lung cancer
(NSCLC) to identify and characterize genes involved in chemotherapy activity. However, the …

The validation of predictive biomarkers to tailor chemotherapy is a key issue in the
development of effective treatment modalities against cancer. Examples of how genetics …

Aim. To evaluate the predictive value of RRM1, ERCCl, and BRCA1 expression in Chinese
NSCLC patients treated with gemcitabine and cisplatin. Methods. Real-time fluorescent …

Purpose We evaluated the efficacy of gemcitabine versus gemcitabine and carboplatin in
patients with advanced non–small-cell lung cancer (NSCLC) and a performance status (PS) …

Methods Eight of the 17 pathway genes were resequenced with DNA samples from Coriell
lymphoblastoid cell lines (LCLs) using Sanger sequencing for all exons, exon–intron …

BACKGROUND: The predictive value of RRM1 to therapeutic efficacy of gemicitabine-
containing chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC) …

Purpose RRM1 is the large subunit of ribonucleotide reductase (RNR), which catalyzes the
rate-limiting step in the production of deoxyribonucleotides (dNTPs) and is essential for DNA …

Background Overexpression of RRM1 and RRM2 has been associated with gemcitabine
resistance. BRCA1 overexpression increases sensitivity to paclitaxel and docetaxel. We …

Aim: We used a panel of 17 non-small-cell lung cancer cell lines to investigate whether the
presence of polymorphisms in the RRM1, ERCC1, ABCB1 and MTHFR genes and …